Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. [electronic resource]
Producer: 20090928Description: 4712-21 p. digitalISSN:- 1557-3265
- Animals
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Diagnostic Imaging -- methods
- Dideoxynucleosides
- Female
- Fluorine Radioisotopes
- Fluorodeoxyglucose F18
- Glucose -- metabolism
- Humans
- Mammary Neoplasms, Experimental -- drug therapy
- Mice
- Mice, Nude
- Mice, Transgenic
- Positron-Emission Tomography
- Prognosis
- Receptor, ErbB-2 -- antagonists & inhibitors
- Reproducibility of Results
- Trastuzumab
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.